Chagas disease
MONDO:0001444A parasitic infection caused by Trypanosoma cruzi. It is transmitted by insect bites. It is characterized by an acute and chronic phase; in the acute phase patients may have fever, malaise, and swelling at the site of the insect bite. In the chronic phase patients develop hepatosplenomegaly, lymphadenopathy, cardiomyopathy and arrhythmias.
Also known as: Chagas disease, Chagas' disease, Trypanosoma cruzi caused disease or disorder, Trypanosoma cruzi disease or disorder, Trypanosoma cruzi infectious disease, infection by trypanosoma cruzi, Chagas-mazza disease, infection caused by trypanosoma cruzi
13 clinical trials for this condition and its sub-types, 12 tagged with Chagas disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New oral drug candidate for two neglected parasitic diseases enters first human testing
Cure CompletedResearchers are running a first-in-human study of LXE408, an experimental oral tablet, to see how safe and well tolerated it is in healthy adults. About 88 healthy volunteers aged 18 to 65 will receive single or multiple ascending doses of LXE408 or a placebo. The study also meas…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Can a common heart drug help chagas patients? new trial results
Disease control CompletedThis study tested whether sacubitril/valsartan (Entresto) works better than enalapril for people with heart failure caused by chronic Chagas disease. Over 900 adults with reduced heart function took part. The goal was to see if the drug could reduce heart-related deaths, hospital…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New chagas drug candidate passes first safety test in small trial
Disease control CompletedThis early-phase trial tested the safety of an experimental drug called ICM20 in 13 adults with Chagas disease who had not been treated before. Participants took ICM20 along with the standard drug benznidazole. The main goal was to check for side effects and see how many people s…
Phase 1 • Sponsor: IC-MedTech Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a shorter pill course beat chagas?
Disease control CompletedThis study tested whether a shorter, lower-dose course of the drug benznidazole works as well as the standard longer treatment for women with Chagas disease. Researchers enrolled 87 women in Argentina who had recently given birth and were infected with the parasite. The goal was …
Phase 3 • Sponsor: Tulane University School of Public Health and Tropical Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Can cutting nerves stop deadly heart rhythms in chagas patients?
Disease control CompletedThis pilot study tested a procedure called bilateral sympathectomy, which cuts certain nerves to the heart, in 45 Chagas disease patients with implantable defibrillators (ICDs) who had frequent dangerous heart rhythms. Participants were randomly assigned to receive the nerve-cutt…
Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Campus sweep: rapid chagas tests could uncover thousands of hidden cases
Diagnosis CompletedThis study tests whether offering a rapid diagnostic test for Chagas disease at a university in Argentina can help find undiagnosed infections and connect people to treatment. Participants are students, faculty, and staff aged 18 and older who get a quick finger-prick test during…
Sponsor: Mundo Sano Foundation • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New drug AN2-502998 tested in healthy people for first time
Knowledge-focused CompletedThis early-stage study tested a new oral drug called AN2-502998 in 72 healthy adults aged 18 to 55. The main goal was to check if the drug is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored side effects and drug le…
Phase 1 • Sponsor: AN2 Therapeutics, Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC